Skye Bioscience, Inc. (SKYE): who owns it and who trades it
As of Nov 16, 2026, SKYE insiders reported 15 open-market sales worth $445K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Andrew J. Schwab (Director), with $445K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Skye Bioscience
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns SKYE
42 funds and institutions reported SKYE shares worth $11.1M at the end of Q2 2026, about 48% of the company. The largest holder is 5AM Venture Management, LLC with 29.0%.
Funds and institutions (13F) 48%Everyone else 52%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| 5AM Venture Management, LLC | 9.68M | 29.01% | $6.7M | – |
| Versant Venture Management, LLC | 2.01M | 6.01% | $1.4M | – |
| Baker Bros. Advisors LP | 1.58M | 4.72% | $1.1M | – |
| Vanguard Capital Management LLC | 763,882 | 2.29% | $529K | – |
| Sphera Funds Management Ltd. | 678,928 | 2.03% | $471K | – |
| Platinum Investment Management Ltd | 233,095 | 0.70% | $162K | – |
| BlackRock, Inc. | 232,874 | 0.70% | $161K | – |
| Geode Capital Management, LLC | 218,055 | 0.65% | $151K | – |
| Millennium Management LLC | 198,524 | 0.59% | $138K | – |
| Vanguard Fiduciary Trust Co | 104,229 | 0.31% | $72.2K | – |
| State Street Corp | 73,830 | 0.22% | $51.2K | – |
| UBS Group AG | 73,800 | 0.22% | $51.1K | – |
| Northern Trust Corp | 56,327 | 0.17% | $39.1K | – |
| Qube Research & Technologies Ltd | 43,082 | 0.13% | $29.9K | – |
| Simplex Trading, LLC | 26,976 | 0.08% | $18.7K | – |
| XTX Topco Ltd | 20,993 | 0.06% | $14.6K | – |
| Engineers Gate Manager LP | 20,194 | 0.06% | $14K | – |
| Group One Trading LLC | 4,589 | 0.01% | $3.2K | – |
| Vanguard Global Advisers, LLC | 4,557 | 0.01% | $3.2K | – |
| Morgan Stanley | 2,469 | 0.01% | $1.7K | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, SKYE insiders reported $0 of open-market purchases and $445K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | Andrew J. Schwab | Director | Sale | 4,528 | $1.61 | $7.3K | Form 4 |
| Sep 23, 2026 | Andrew J. Schwab | Director | Sale | 114,851 | $1.61 | $185K | Form 4 |
| Sep 22, 2026 | Andrew J. Schwab | Director | Sale | 1,088 | $1.65 | $1.8K | Form 4 |
| Sep 22, 2026 | Andrew J. Schwab | Director | Sale | 27,612 | $1.65 | $45.6K | Form 4 |
| Sep 16, 2026 | Andrew J. Schwab | Director | Sale | 32,607 | $1.91 | $62.3K | Form 4 |
| Sep 16, 2026 | Andrew J. Schwab | Director | Sale | 1,285 | $1.91 | $2.5K | Form 4 |
| Aug 20, 2026 | Andrew J. Schwab | Director | Sale | 1,159 | $0.32 | $371 | Form 4 |
| Aug 20, 2026 | Andrew J. Schwab | Director | Sale | 6,495 | $0.32 | $2.1K | Form 4 |
| Aug 20, 2026 | Andrew J. Schwab | Director | Sale | 46 | $0.32 | $15 | Form 4 |
| Aug 19, 2026 | Andrew J. Schwab | Director | Sale | 57,476 | $0.35 | $20.1K | Form 4 |
| Aug 19, 2026 | Andrew J. Schwab | Director | Sale | 409 | $0.35 | $143 | Form 4 |
| Aug 19, 2026 | Andrew J. Schwab | Director | Sale | 10,255 | $0.35 | $3.6K | Form 4 |
| Aug 18, 2026 | Andrew J. Schwab | Director | Sale | 253,080 | $0.38 | $96.2K | Form 4 |
| Aug 18, 2026 | Andrew J. Schwab | Director | Sale | 1,830 | $0.38 | $695 | Form 4 |
| Aug 18, 2026 | Andrew J. Schwab | Director | Sale | 45,090 | $0.38 | $17.1K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Andrew J. Schwab | Director, 10% owner | – | $445K | Sep 23, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SKYE short interest
129,314 SKYE shares are sold short. Over the last 12 reports the number of shares short went down 18%.
As of Oct 30, 2026, 129,314 SKYE shares were sold short, down 7.8% from the report before. At the average daily volume of 20,583 shares, buying them all back would take about 6.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 129,314 | – | -8% | 20,583 | 6.3 |
| Oct 15, 2026 | 140,313 | – | -5% | 28,640 | 4.9 |
| Sep 30, 2026 | 147,954 | – | +26% | 85,208 | 1.7 |
| Sep 15, 2026 | 14,636 | 0.33% | -9% | 86,091 | 1.4 |
| Aug 31, 2026 | 16,098 | 0.36% | -89% | 217,817 | 1.0 |
| Aug 14, 2026 | 150,450 | 3.40% | -9% | 799,341 | 1.5 |
| Jul 31, 2026 | 164,600 | 3.95% | +25% | 104,833 | 12.6 |
| Jul 15, 2026 | 131,795 | 3.16% | +11% | 132,231 | 8.0 |
| Jun 30, 2026 | 118,832 | 2.85% | -2% | 133,002 | 7.2 |
| Jun 15, 2026 | 121,846 | 2.92% | -13% | 202,290 | 4.8 |
| May 29, 2026 | 140,792 | 3.37% | -11% | 170,323 | 6.6 |
| May 15, 2026 | 158,522 | 3.80% | -1% | 175,331 | 7.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Skye Bioscience company events
Skye Bioscience filed 15 reports on Form 8-K in the last 12 months, 8 of them about an important change (leadership, listing, control). The latest was on Sep 11, 2026.
- Sep 11, 2026LeadershipJohn P. Sharp resigned as Chief Financial Officer and principal financial and accounting officer of the Company, effective as of the Effective Date. Filing
- Aug 24, 2026AgreementAs previously disclosed on the Current Report on Form 8-K filed by Skye Bioscience, Inc., a Nevada corporation, with the U.S. Securities and Exchange Commission on August 14, 2026, concurrently with the entry by the Company into (1) that certain Transaction Agreement with Redx Pharma Limited, a… Filing
- Aug 20, 2026SharesAmended an earlier report. Changed the rights of its shareholders. Filing
- Aug 19, 2026ListingSkye Bioscience, Inc. received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, based on the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, the Company’s stockholders’ equity was ($497,307)… Filing
- Aug 14, 2026ControlTo the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Filing
- Jun 23, 2026AnnouncementAs previously disclosed on a Current Report on Form 8-K filed by Skye Bioscience, Inc. on May 13, 2026, the Company received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, based on the Company’s Quarterly Report on Form… Filing
- May 29, 2026VoteReported shareholder vote results. Filing
- May 15, 2026ListingSkye Bioscience, Inc. received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, based on the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, the Company’s stockholders’ equity was $9.01… Filing
- Apr 6, 2026LeadershipAmended an earlier report. Option Repricing The total number of shares of common stock of the Company underling all Repriced Options is 2,458,158 shares. Filing
- Apr 3, 2026LeadershipUpon recommendation of the Compensation Committee of the Board of Directors of Skye Bioscience, Inc., the Board approved a stock option repricing, effective as of the Repricing Date, of all outstanding stock options held by current full-time employees, including the Company's executive officers… Filing
- Mar 19, 2026ListingSkye Bioscience, Inc. received a deficiency letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.001 per share had been below… Filing
- Mar 10, 2026ResultsReleased financial results. Filing
- Feb 20, 2026LeadershipThe Company and Kaitlyn Arsenault determined that Ms. Arsenault will step down from her position as Chief Financial Officer of the Company, effective February 20, 2026 to pursue new professional opportunities. Filing
- Feb 2, 2026AnnouncementThe Company reported the following interim results from the combination cohort of its Phase 2a extension study: • 19 participants in the combination cohorts completed week 26 and were eligible for the extension study, which continued in a blinded manner for 26 weeks, maintaining their original… Filing
- Dec 23, 2025AgreementSkye Bioscience, Inc. entered into a Non-exclusive Collaboration and License Agreement with Halozyme, Inc. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Skye Bioscience financials
Famous investors that hold SKYE
2 of the 50 well-known investors we track reported holding SKYE in their latest 13F filing. The largest position is Ken Griffin's, worth $185K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 114,938 | $185K | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 14,611 | $23.5K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named SKYE in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 14, 2026 | TANG CAPITAL MANAGEMENT, LLC | 13G | 6.0% |
| Oct 14, 2026 | TANG CAPITAL MANAGEMENT, LLC | 13G | 6.0% |
Questions about Skye Bioscience, Inc. (SKYE) stock
Who owns the most SKYE stock?
The largest reported owner of Skye Bioscience, Inc. (SKYE) is 5AM Venture Management, LLC, with 29.0% of the company. In total, 42 funds and institutions reported holding SKYE at the end of Q2 2026, together about 48% of the shares. See the largest owners.
Are SKYE insiders buying or selling?
In the last 12 months, SKYE insiders reported no open-market purchases and 15 sales worth $445K. The latest trade was on Sep 23, 2026. See every trade.
What is the short interest in SKYE?
As of Oct 30, 2026, 129,314 SKYE shares were sold short, down 7.8% from the report before. At the average daily volume of 20,583 shares, buying them all back would take about 6.3 trading days (days to cover). See the history.
Which famous investors hold SKYE?
2 of the 50 well-known investors we track reported SKYE in their latest 13F filing, including Ken Griffin, Israel Englander. The largest position is worth $185K. See all holders.
Executive pay
Skye Bioscience's chief executive was paid a total of $1.4M for the year ended Dec 31, 2025, down 78% from $6.1M the year before. In the last 12 months, Skye Bioscience's executives and directors bought no stock on the open market and sold $445K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.